Revvity Inc
NYSE:RVTY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Revvity Inc
Other Liabilities
Revvity Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Revvity Inc
NYSE:RVTY
|
Other Liabilities
$148.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-11%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Liabilities
$4.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Liabilities
$5.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Waters Corp
NYSE:WAT
|
Other Liabilities
$294.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Liabilities
$621m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Liabilities
$913m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
17%
|
|
Revvity Inc
Glance View
In the fast-evolving landscape of life sciences and diagnostics, Revvity Inc. stands as a vital player, driving innovation and delivering critical solutions to a diverse array of sectors. Established with a focus on precision, Revvity leverages its expertise in diagnostics and scientific services to address pressing global health challenges. The company operates by providing advanced analytical instruments, reagents, and software, enabling researchers and healthcare providers to conduct intricate analyses with unmatched reliability. Their offerings are crucial in areas such as prenatal and neonatal screening, as well as infectious disease detection, where accuracy is of paramount importance. Revenue generation at Revvity hinges on a hybrid model that includes product sales, service contracts, and licensing. By supplying state-of-the-art laboratory equipment, along with complementary services and software, the company creates a comprehensive ecosystem for research and diagnostic testing. The breadth of their portfolio appeals to a varied clientele, from hospital labs to large research institutions, ensuring a steady and diversified income stream. Furthermore, their commitment to research and development fosters long-term partnerships and secures their place at the forefront of scientific advancement, making Revvity a linchpin in both the healthcare and scientific communities.
See Also
What is Revvity Inc's Other Liabilities?
Other Liabilities
148.1m
USD
Based on the financial report for Dec 28, 2025, Revvity Inc's Other Liabilities amounts to 148.1m USD.
What is Revvity Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
-11%
Over the last year, the Other Liabilities growth was -2%. The average annual Other Liabilities growth rates for Revvity Inc have been -4% over the past three years , -31% over the past five years , and -11% over the past ten years .